logo
Plus   Neg
Share
Email

Halozyme: Genentech Reports Positive Outcome From Phase III Study Using ENHANZE

Halozyme Therapeutics, Inc. (HALO) said the phase III FeDeriCa trial, a global study conducted by Genentech using combination of pertuzumab and trastuzumab using Halozyme's ENHANZE drug delivery technology, met its primary endpoint. Halozyme said the results of the study is an important development for the ENHANZE technology.

Helen Torley, CEO, said: "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
RELATED NEWS
Follow RTT